Prosecution Insights
Last updated: October 25, 2026
Application No. 17/930,751

RECYCLED BIODEGRADABLE PLASTIC ADDITIVE, BIODEGRADABLE RECYCLED FIBERS AND METHOD OF MAKING SAME

Non-Final OA §102§103§112
Filed
Sep 09, 2022
Priority
Sep 15, 2021 — provisional 63/244,492
Examiner
USELDING, JOHN E
Art Unit
1763
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Everywhere Apparel Inc.
OA Round
3 (Non-Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
72%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
700 granted / 1300 resolved
-11.2% vs TC avg
Strong +18% interview lift
Without
With
+17.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
64 currently pending
Career history
1368
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
44.8%
+4.8% vs TC avg
§102
15.0%
-25.0% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1300 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/2/2026 has been entered. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-6, 8, 9 and 22-23 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The limitation “wherein the polymer additive composition is free of added biological entities having a polyester-degrading activity” is not supported by the original specification. The specification does not support the breadth of “biological entities”. Claim 21 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The limitation “without enzymatic degradation by added biological entities” is not supported by the original specification. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 2, 5, 6, 8 and 22-23 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Zhao et al. (CN 108221079A). Regarding claims 1, 5, 6 and 23: Zhao et al. teach a polymer composition comprising 96 wt% polycaprolactone and 3 wt% of hydroxyapatite [Examples]. Since the claimed amount of the claimed catalyst is present, it is effective to catalyze biodegradation of the polycaprolactone. The courts have stated that a chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 15 USPQ2d 1655, (Fed. Cir. 1990). See also In re Best, 562 F.2d 1252, 195 USPQ 430, (CCPA 1977). "Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established." Further, if it is the applicant's position that this would not be the case, evidence would need to be provided to support the applicant's position. Regarding claim 2: Zhao et al. teach a particle size of 20-30 nm [0014; Examples]. Regarding claim 8: The granules of Zhao et al. [Examples] is considered to be a masterbatch pellet. Regarding claim 22: Zhao et al. teach a length (a size) of 200-250 nm (0.2 to 0.25 microns) [0014; Examples]. Claim(s) 21 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Zhao et al. (CN 108221079A). Zhao et al. teach a polymer composition comprising 96 wt% polycaprolactone and 3 wt% of hydroxyapatite [Examples]. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 3, 4 and 9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Zhao et al. (CN 108221079A) as applied to claims 1 and 2 above further in view of Guemard et al. (2018/0142097). Regarding claims 3 and 4: Zhao et al. fail to teach a thermoplastic carrier polymer. However, Guemard et al. teach in an analogous composition that adding polyethylene terephtahate [0070-0071; 0088] advantageously improves the properties of the composition [0070]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to add polyethylene terephthalate as taught by Guemard et al. to the composition of Zhao et al. to advantageously improve the properties of a degradable polymer composition. Regarding claim 9: The granules of Zhao et al. [Examples] is considered to be a masterbatch pellet. Claim(s) 21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Guemard et al. (2018/0142097). Guemard et al. teach an additive composition comprising 65 to 95% of polycaprolactone (biodegradable poymer) [0010; Example 6] and 2 to 25 wt% of at least one anti-acid filler (biodegradation catalyst) [0052, 0078]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to select hydroxyapatite [0052] as the anti-acid filler in Guemard et al. The hydroxyapatite of Guemard et al. is “effective to catalyze biodegradation”. The ranges taught overlap the claimed ranges. The subject matter as a whole would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention, since it has been held that choosing the overlapping portion, of the range taught in the prior art and the range claimed by the applicant, has been held to be a prima facie case of obviousness, see In re Malagari, 182 USPQ 549, In re Geisler 43 USPQ2d 1365 (Fed. Cir. 1997); In re Woodruff, 16 USPQ2d 1934 (CCPA 1976) and MPEP 2144.05. The claim contains product by process limitations. Process limitations in product claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. "In re Thorpe, 227 USPQ 964, 966 (Fed. Cir. 1985). Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. In re Best, 562 F.2d at 1255, 195 USPQ at 433. See also Titanium Metals Corp. v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985). The limitation “catalyzed…without enzymatic degradation by added biological entities” is a product by process limitation that does not provide a structural difference from Geumard et al. Response to Arguments Applicant's arguments filed 7/2/2026 have been fully considered but they are not persuasive. The applicant has made the argument that Guemard requires biological entities having a polyester-degrading activity. This is not persuasive because claim 21 contains product by process limitations that do no exclude a biodegradation catalyst in the final structure. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN USELDING whose telephone number is (571)270-5463. The examiner can normally be reached on M-F 8am to 6:30pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Del Sole can be reached on 571-272-1130. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN E USELDING/ Primary Examiner, Art Unit 1763
Read full office action

Prosecution Timeline

Sep 09, 2022
Application Filed
Aug 28, 2025
Non-Final Rejection mailed — §102, §103, §112
Mar 02, 2026
Response Filed
Apr 17, 2026
Final Rejection mailed — §102, §103, §112
Jun 16, 2026
Response after Non-Final Action
Jul 02, 2026
Request for Continued Examination
Jul 03, 2026
Response after Non-Final Action
Sep 28, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767789
CURABLE RESIN COMPOSITION
3y 3m to grant Granted Oct 20, 2026
Patent 12760175
Polyoxymethylene Polymer Composition For Rotational Molding Applications
4y 6m to grant Granted Oct 13, 2026
Patent 12760194
Water-Based Ink Jet Ink Composition
3y 8m to grant Granted Oct 13, 2026
Patent 12753119
UNCHARGED CLAY BLOCKING AGENT
4y 1m to grant Granted Oct 06, 2026
Patent 12753262
PROCESS FOR THE REDUCTION OF REGIOISOMER WHERE THE DOUBLE BOND IS SHIFTED FROM ETHYLENICALLY UNSATURATED ALKOXYLATED ALCOHOLS
3y 6m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
72%
With Interview (+17.9%)
2y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1300 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month